Logotype for Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics (LCTX) investor relations material

Lineage Cell Therapeutics Q3 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Lineage Cell Therapeutics Inc
Q3 2025 earnings summary6 Nov, 2025

Executive summary

  • Advanced OpRegen program with eight new clinical sites and durable 36-month efficacy, supported by Roche/Genentech and RMAT designation.

  • Strategic partnership with William Demant Invest secured up to $12 million for Resonance (ANP1) hearing loss program, validating the platform and funding preclinical milestones.

  • Initiated large-scale manufacturing for iLET Cell (Type 1 Diabetes), with early work suggesting scalable islet cell production and a go/no-go decision expected next quarter.

  • OPC-1 program dosed first patient in DOSED study for spinal cord injury, with no significant safety events and CIRM grant finalist status for up to $7 million in non-dilutive funding.

  • Business model leverages internal development and strategic partnerships, focusing on scalable pluripotent cell platform and value creation.

Financial highlights

  • Q3 2025 revenues were $3.7 million, down $0.1 million year-over-year; nine-month revenue was $7.9 million, up 20% year-over-year.

  • Operating expenses for Q3 2025 were $7.5 million, with R&D at $3.3 million and G&A at $4.2 million.

  • Net loss for Q3 2025 was $29.8 million ($0.13/share), mainly due to a $26.6 million non-cash warrant liability remeasurement; nine-month net loss was $64.4 million.

  • Cash, cash equivalents, and marketable securities totaled $40.5 million as of September 30, 2025, expected to fund operations into Q2 2027.

  • Recorded a $14.8 million non-cash impairment charge for abandonment of the VAC platform.

Outlook and guidance

  • Cash runway extends into Q2 2027, not including potential milestone payments from Roche/Genentech or CIRM grant funds.

  • Expects continued momentum in 2026, driven by OpRegen progress, expanded partnerships, and manufacturing innovations.

  • Up to $36 million in potential proceeds from warrant exercises and $38.7 million available under the ATM program.

  • Awaiting CIRM grant decision, which could offset up to 50% of OPC-1 trial costs and free up capital for other programs.

  • Ongoing pursuit of additional capital through equity, grants, and collaborations.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Lineage Cell Therapeutics earnings date

Logotype for Lineage Cell Therapeutics Inc
Q4 202512 Mar, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Lineage Cell Therapeutics earnings date

Logotype for Lineage Cell Therapeutics Inc
Q4 202512 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Lineage Cell Therapeutics Inc is a biotechnology company developing cell-based therapies for degenerative diseases. The company focuses on regenerative medicine approaches for ophthalmology, neurology, and oncology, using proprietary cell manufacturing platforms. The company is headquartered in Carlsbad, California, and its shares are listed on the NYSE American.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage